Yahoo Finance • 3 months ago
We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Vera Therapeutics Inc. (NASDAQ:VERA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps... Full story
Yahoo Finance • last year
Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN Announced analysis of Phase 2b ORIGIN study showing reso... Full story
Yahoo Finance • last year
Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations provide further safety analysis of Phase 2b... Full story
Yahoo Finance • last year
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story
Yahoo Finance • last year
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating ataciceptin IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potent... Full story
Yahoo Finance • last year
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk p... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dis... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story
Yahoo Finance • 2 years ago
NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA). Such investors are advised to contact Robert S. Willoughby at n... Full story
Yahoo Finance • 2 years ago
Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept i... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story
Yahoo Finance • 2 years ago
NEW YORK, Jan. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA). Such investors are advised to contact Robert S. Willoughby at... Full story
Yahoo Finance • 2 years ago
The Nasdaq Composite (NASDAQINDEX: ^IXIC) tried to bounce back on Wednesday morning, seeking to recover losses from the first trading day of 2023. As of shortly after the opening bell, the Nasdaq had moved up by more than half a percent. I... Full story
Yahoo Finance • 2 years ago
Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in protein... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story
Yahoo Finance • 2 years ago
Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy topline data planned to be presented in early Q1 2023 Initiated pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis Strong balance sheet with $114.4 million... Full story
Yahoo Finance • 2 years ago
New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN)Atacicept is the first therapeutic to show reduction in all of the three first hits of IgAN pathogenesis –... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological d... Full story